Japan 日本


アドバンスト・バイオニクスは、人工内耳システムに特化して開発を行っているグローバル企業です。 2009 年にSonova(ソノバ)ホールディングにより吸収され、それ以来Phonak(フォナック)社と業務連携しました。 Phonak(フォナック)社の音声処理技術を活かした、人工内耳インプラント技術を開発しています。


「人生を豊かにする」医療用埋込装置を開発するというビジョンのもと、1993年にAlfred E. Mann(アルフレッド・E・マン)により創設されました。


AB evolved from two highly successful companies that developed and marketed innovative medical devices; one created new generation pacemakers, and the other developed microinfusion systems (miniature drug delivery pumps used in the treatment of diabetes). The technology behind AB’s first cochlear implant system came from the pioneering research at the University of California, San Francisco.

Since its inception, AB has consistently made industry-leading advancements in technology innovations that have helped make a difference in the lives of thousands of families worldwide.

Today, AB offers the most sophisticated cochlear implant system on the market with five times more sound resolution than its competitors, designed to allow recipients to go beyond deciphering speech to hearing music.

Now working with Phonak under the Sonova Group, AB has access to industry-leading engineering and technologies for products currently under development. These revolutionary products are designed to deliver unparalleled hearing performance, comfort, and reliability for recipients.